LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

COVID-19 Patients with Lymphocytopenia Are Likely to Suffer Severe Disease Symptoms

By LabMedica International staff writers
Posted on 22 Jul 2020
Image: A scanning electron microscope image of normal circulating human blood showing red blood cells, several types of white blood cells including lymphocytes, a monocyte, a neutrophil and many small disc-shaped platelets (Photo courtesy of [U.S.] National Cancer Institute)
Image: A scanning electron microscope image of normal circulating human blood showing red blood cells, several types of white blood cells including lymphocytes, a monocyte, a neutrophil and many small disc-shaped platelets (Photo courtesy of [U.S.] National Cancer Institute)
An easily recognizable feature in blood samples may be an indicator of whether a COVID-19 patient will be likely to suffer from a severe form of the disease.

Lymphocytopenia - abnormally low levels of white blood cells - is a common systemic manifestation of many viral illnesses; in particular, other coronaviruses like Severe Acute Respiratory Syndrome coronavirus (SARS‐CoV) and Middle Eastern Respiratory Syndrome coronavirus (MERS‐CoV) have been demonstrated to cause lymphocytopenia. However, few studies have examined whether lymphocytopenia found at the time of admission to the hospital is helpful in understanding the disease course.

For this reason, investigators at the University of Texas Health Science Center at Houston (USA) studied a cohort of hospital patients diagnosed with COVID‐19 to determine whether lymphocytopenia, found at the time of admission to the hospital, was associated with disease severity and other clinical outcomes.

For this study, the investigators analyzed blood samples obtained from 57 patients from a local Houston hospital. Results revealed that lymphocyte count was lower and lymphocytopenia more frequent in patients admitted to the Intensive Care Unit (ICU), a marker of disease severity, relative to those who were not. In addition, patients with lymphocytopenia were more likely to develop an acute kidney injury (AKI), a marker of organ failure, during admission.

The investigators integrated basic demographic, clinical, and laboratory data to formulate a theory explaining the relationship between lymphocytopenia at the time of hospital admission and clinical outcomes. Furthermore, they said that their findings supported the hypothesis that lymphocytopenia could be an early, useful, and easily obtained, prognostic factor in determining the clinical course and disease severity of a patient admitted to the hospital for COVID‐19.

“Because of the uncertainty surrounding the implications of this virus, we knew there needed to be a prognostic factor that could aid hospital workers in managing COVID-19,” said senior author Dr. Ahmad Farooq, assistant professor of gastroenterology at the University of Texas Health Science Center at Houston. “In this study, we discovered evidence of a relationship between lymphocytopenia and disease severity that could really help clinicians prepare for critically ill patients. The finding of an association with AKI warrants further research. Nevertheless, it is apparent here that lymphocytopenia may serve as a prognostic marker for AKI in patients with COVID-19.”

The link between lymphocytopenia and severity of COVID-19 infection was described in the July 10, 2020, online edition of the International Journal of Laboratory Hematology.

Related Links:
University of Texas Health Science Center at Houston

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more